-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Arcellx (NASDAQ:ACLX) Price Target Raised to $35.00 at Needham & Company LLC
Arcellx (NASDAQ:ACLX) Price Target Raised to $35.00 at Needham & Company LLC
Arcellx (NASDAQ:ACLX – Get Rating) had its price target hoisted by Needham & Company LLC from $31.00 to $35.00 in a research note issued to investors on Monday, The Fly reports. The brokerage currently has a buy rating on the stock.
Several other analysts have also weighed in on ACLX. Guggenheim initiated coverage on Arcellx in a report on Monday, October 31st. They issued a buy rating and a $36.00 target price on the stock. Piper Sandler upped their price objective on Arcellx from $96.00 to $104.00 in a research report on Friday, December 9th. SVB Leerink reduced their price objective on Arcellx to $35.00 in a research report on Thursday, November 24th. Finally, Barclays upped their price objective on Arcellx from $25.00 to $38.00 and gave the company an overweight rating in a research report on Monday. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of Buy and a consensus target price of $43.88.
Get Arcellx alerts:Arcellx Stock Down 6.0 %
Arcellx stock opened at $31.03 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 6.48 and a current ratio of 6.48. The firm has a market capitalization of $1.36 billion and a price-to-earnings ratio of -0.70. Arcellx has a fifty-two week low of $6.03 and a fifty-two week high of $33.99. The stock's fifty day moving average is $21.60 and its two-hundred day moving average is $19.58.
Insider Buying and Selling
In related news, insider Christopher Heery sold 12,500 shares of the stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $30.03, for a total transaction of $375,375.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.Hedge Funds Weigh In On Arcellx
Several large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its position in Arcellx by 117.2% during the third quarter. Bank of New York Mellon Corp now owns 120,637 shares of the company's stock worth $2,264,000 after buying an additional 65,101 shares during the period. California State Teachers Retirement System raised its holdings in shares of Arcellx by 177.7% in the 3rd quarter. California State Teachers Retirement System now owns 11,673 shares of the company's stock worth $219,000 after purchasing an additional 7,470 shares during the period. Alliancebernstein L.P. purchased a new position in shares of Arcellx in the 3rd quarter worth about $404,000. State Street Corp raised its holdings in shares of Arcellx by 761.1% in the 3rd quarter. State Street Corp now owns 1,514,025 shares of the company's stock worth $28,418,000 after purchasing an additional 1,338,208 shares during the period. Finally, Tri Locum Partners LP purchased a new position in shares of Arcellx in the 3rd quarter worth about $804,000. 92.30% of the stock is currently owned by hedge funds and other institutional investors.
Arcellx Company Profile
(Get Rating)
Arcellx, Inc, a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).
Featured Stories
- Get a free copy of the StockNews.com research report on Arcellx (ACLX)
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.
Arcellx (NASDAQ:ACLX – Get Rating) had its price target hoisted by Needham & Company LLC from $31.00 to $35.00 in a research note issued to investors on Monday, The Fly reports. The brokerage currently has a buy rating on the stock.
据The Fly报道,在周一发布给投资者的一份研究报告中,Needham&Company LLC将Arcell(纳斯达克:ACLX-GET评级)的目标价从31.00美元上调至35.00美元。该经纪公司目前对该股的评级为买入。
Several other analysts have also weighed in on ACLX. Guggenheim initiated coverage on Arcellx in a report on Monday, October 31st. They issued a buy rating and a $36.00 target price on the stock. Piper Sandler upped their price objective on Arcellx from $96.00 to $104.00 in a research report on Friday, December 9th. SVB Leerink reduced their price objective on Arcellx to $35.00 in a research report on Thursday, November 24th. Finally, Barclays upped their price objective on Arcellx from $25.00 to $38.00 and gave the company an overweight rating in a research report on Monday. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of Buy and a consensus target price of $43.88.
其他几位分析师也加入了对ACLX的看法。古根海姆在10月31日星期一的一份报告中发起了对Arcell的报道。他们对该股发布了买入评级和36.00美元的目标价。在12月9日星期五的一份研究报告中,派珀·桑德勒将Arcell的目标价从96美元上调至104.00美元。SVB Leerink在11月24日星期四的一份研究报告中将Arcell的目标价下调至35.00美元。最后,巴克莱在周一的一份研究报告中将Arcellx的目标价从25.00美元上调至38.00美元,并给予该公司增持评级。根据MarketBeat.com的数据,8名研究分析师对该股的评级为买入,该公司目前的共识评级为买入,共识目标价为43.88美元。
Arcellx Stock Down 6.0 %
Arcell股价下跌6.0%
Arcellx stock opened at $31.03 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 6.48 and a current ratio of 6.48. The firm has a market capitalization of $1.36 billion and a price-to-earnings ratio of -0.70. Arcellx has a fifty-two week low of $6.03 and a fifty-two week high of $33.99. The stock's fifty day moving average is $21.60 and its two-hundred day moving average is $19.58.
Arcell股票周一开盘报31.03美元。该公司的负债权益比率为0.11,速动比率为6.48,流动比率为6.48。该公司市值为13.6亿美元,市盈率为-0.70倍。Arcellx的股价为52周低点6.03美元,52周高位为33.99美元。该股的50日移动均线切入位为21.60美元,200日移动均线切入位为19.58美元。
Insider Buying and Selling
内幕买卖
Hedge Funds Weigh In On Arcellx
对冲基金入股Arcellx
Several large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its position in Arcellx by 117.2% during the third quarter. Bank of New York Mellon Corp now owns 120,637 shares of the company's stock worth $2,264,000 after buying an additional 65,101 shares during the period. California State Teachers Retirement System raised its holdings in shares of Arcellx by 177.7% in the 3rd quarter. California State Teachers Retirement System now owns 11,673 shares of the company's stock worth $219,000 after purchasing an additional 7,470 shares during the period. Alliancebernstein L.P. purchased a new position in shares of Arcellx in the 3rd quarter worth about $404,000. State Street Corp raised its holdings in shares of Arcellx by 761.1% in the 3rd quarter. State Street Corp now owns 1,514,025 shares of the company's stock worth $28,418,000 after purchasing an additional 1,338,208 shares during the period. Finally, Tri Locum Partners LP purchased a new position in shares of Arcellx in the 3rd quarter worth about $804,000. 92.30% of the stock is currently owned by hedge funds and other institutional investors.
几家大型投资者最近增持或减持了该公司的股份。纽约梅隆银行(Bank Of New York Mellon Corp)在第三季度将其在Arcell的持仓提高了117.2%。纽约梅隆银行(Bank Of New York Mellon Corp)目前持有120,637股该公司股票,价值2,264,000美元,在此期间又购买了65,101股。加州教师退休制度在第三季度将其持有的Arcell股票增加了177.7%。加利福尼亚州教师退休系统现在拥有11,673股该公司的股票,价值21.9万美元,在此期间又购买了7,470股。联合伯恩斯坦公司在第三季度购买了价值约40.4万美元的Arcell股票的新头寸。道富银行在第三季度增持了761.1%的Arcell股票。道富银行目前持有1,514,025股该公司股票,价值28,418,000美元,在此期间又购买了1,338,208股。最后,Tri Locum Partners LP在第三季度购买了价值约80.4万美元的Arcellx新股票头寸。92.30%的股票目前由对冲基金和其他机构投资者持有。
Arcellx Company Profile
Arcellx公司简介
(Get Rating)
(获取评级)
Arcellx, Inc, a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).
Arcell,Inc.是一家临床阶段的生物技术公司,致力于为癌症和其他不治之症患者开发各种免疫疗法。该公司主要的ddCAR候选产品是CART-ddBCMA,这是一种治疗复发或难治性(r/r)多发性骨髓瘤(MM)患者的第一阶段临床试验。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Arcellx (ACLX)
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
- 免费获取StockNews.com关于Arcell的研究报告(ACLX)
- 拖拉机库存能否突破杯柄收购点?
- 现在不是购买Lennar的时候,但时机即将到来
- 马伦汽车公司改变游戏规则的消息
- 通货膨胀和能源危机是两列相撞的货运列车--以下是如何做好准备的
- 企业产品合作伙伴是否得到公平评价?
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.
接受Arcell Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收Arcell和相关公司的最新新闻和分析师评级的每日简明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧